Recently, Hisicore innovative drugsHSK36357capsuleⅠThe phase I clinical trial completed the enrollment and medication administration for the first participant. This timeⅠThe phase I clinical trial is forEvaluationHSK36357capsuleInChinaHealthadulthoodSafety, tolerance, pharmacokinetics in subjects, and the effect of food on pharmacokinetics, estimated number of subjects84Example.

HSK36357It is a completely new neuropathic pain treatment drug independently developed by Hisicor, with independent intellectual property rights. Non-clinical studies have shown that this product has significant analgesic effects in the body and high central safety, providing an oral therapy with a novel therapeutic mechanism for various types of neuropathic pain. The drug has received a clinical trial notice and formal trials have begun.China-Japan Friendship HospitalPhase I clinical trial is underway, the first dose administration was completed recently, and the project is progressing smoothly.

Neuropathic pain is pain caused by damage or disease in the somatic sensory system. The disease has a long duration, and clinical manifestations are complex, including sensory impairment, motor disorders, autonomic nervous system dysfunction, and pain symptoms in the corresponding nerve territories. It is often accompanied by anxiety, depression, sleep disorders, and other issues, significantly affecting the quality of life of patients. There is currently a lack of effective medical treatments for neuropathic pain, and there is an urgent need for new drugs that improve efficacy and reduce adverse effects. No products targeting this mechanism have been launched domestically or internationally yet. The development prospects are promising, and the large unmet clinical needs indicate a good market potential.

Pre-clinical studies show that,HSK36357It exhibits good pharmacological activity in vitro and will provide a new treatment option for patients with neural pain, possessing significant clinical and social importance.